News

Diabetes Research
20.07.2016

Prof. Dr. Matthias Tschöp a multiple award-winning scientist

Neuherberg, July 15, 2016. With more than 400 million people affected, diabetes poses a permanently growing challenge to global health. Through his outstanding work in the field of metabolic research, Matthias Tschöp from the Helmholtz Zentrum München makes a significant contribution to the development of new therapies. In recognition of his work, he has been elected a member of Academia Europaea and awarded the Victor Mutt prize 2016.

Matthias Tschöp

Prof. Dr. Matthias Tschöp, Source: Helmholtz Zentrum München

Founded in 1988, the Academia Europaea is a non-governmental scientific society with the aim to bring outstanding European researchers from various disciplines into dialogue and networking. Now Prof. Dr. Matthias Tschöp from the Helmholtz Zentrum München has joined this scientific society. The exclusive membership is acquired upon receipt of an invitation proposed by an expert committee. The decision to grant membership must be confirmed by a council.  Currently, the society has around 3,500 members, including 54 Nobel Prize winners.

In addition to these honors, Tschöp was also awarded the Viktor Mutt prize 2016 by the Regulatory Peptide Society on July 14, in Rouen, France, for his work. The jury praised, in particular, the originality of his research and the strong translational orientation in the development of active ingredients. As an example, the jury mentioned the development of the so-called triple-hormone against obesity and diabetes.

Matthias Tschöp is Director of the Institute for Diabetes and Obesity at the Helmholtz Zentrum München and holds the Chair of the Division of Metabolic Diseases at the Technische Universität München. As a medical doctor, he is driven by the need to profitably translate the knowledge gained into practice. "Diabetes is one of the most common diseases and a major threat to our society," he says very earnestly.  "We should lose no time in developing effective and safer therapies and new drugs tailored to the needs of the individual patient."

 

Further information

The Helmholtz Zentrum München, the German Research Center for Environmental Health, pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München is headquartered in Neuherberg in the north of Munich and has about 2,300 staff members. It is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members.

The Institute of Diabetes and Obesity (IDO) studies the diseases of the metabolic syndrome by means of systems biological and translational approaches on the basis of cellular systems, genetically modified mouse models and clinical intervention studies. It seeks to discover new signaling pathways in order to develop innovative therapeutic approaches for the personalized prevention and treatment of obesity, diabetes and their concomitant diseases. IDO is part of the Helmholtz Diabetes Center (HDC).